Conference Call and Webcast: Q2/H1 2020 Financial Results
MorphoSys’ Management team will host a conference call and webcast on August 6, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present the second quarter and first half financial results 2020 and the further outlook for 2020.
Date of the conference call: Thursday, August 6, 2020
Time: 2:00pm CEST (1:00pm BST, 8:00am EDT)
Germany: +49 69 201 744 220
United Kingdom: +44 203 009 2470
USA: +1 877 423 0830
Participant PIN: 43014391#
Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start.
Go to Webcast (slides only)*
Got to Webcast (audio and slides)*
A replay of the conference will also be available at the corporate website following the live event.
*Correction to the Conference Call and Webcast on the release of MorphoSys AG's Second Quarter and First Half of 2020 Results: Royalty payments to Xencor Inc. for product sales outside the U.S. are solely payable by MorphoSys AG
In today's conference call and webcast on the release of MorphoSys AG's second quarter and first half of 2020 results on August 6, 2020 the following question was raised:
“The second question would relate, a bit more technical, to the Xencor royalties you have to pay, right. I remember that was somewhere in the high single to low double digit range of the global net sales. Ok, U.S. is a profit sharing deal, but outside the U.S., who pays those royalties? If you receive, let’s assume 20 percent royalties from Incyte and on top of that and you would pay 10 to […] royalties to Xencor. So, how is the split between yourself and Incyte in the ex-U.S. territory?”
Jens Holstein, Chief Financial Officer of MorphoSys AG, answered as follows:
„You had the question on the Xencor royalties and you phrased it correctly. The Xencor royalties are in the high single digit to low double digit area. And for Europe that means, as we are not responsible for the commercialization in Europe, we are actually not paying those royalties; we receive the royalties in the royalty range of the mid-teens to mid-twenties from our partner Incyte and, in that case, it is their business, not ours.”
MorphoSys herewith corrects the answer to this question as follows:
Under the collaboration and license agreement with Incyte Corporation, MorphoSys AG will receive tiered royalties on ex-U.S. net sales of tafasitamab in a mid-teens to mid-twenties percentage range of net sales, as previously announced on January 13, 2020. However, the related royalty payments to Xencor Inc. for product sales outside the U.S. are payable solely by MorphoSys AG and not by Incyte.
|200806_Presentation Q2 2020||1.82 MB|